- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Daiichi Sankyo Concludes pCPA Letter of Intent for Vanflyta in Newly Diagnosed FLT3-ITD Positive AML | 6 | CNW | ||
| Mi | Daiichi Sankyo Europe GmbH: Daiichi Sankyo Europe bekräftigt sein Engagement für eine patientenorientierte Versorgung mit einer umfassenden Datenpräsentation auf dem EAS-Kongress 2026 | 277 | Business Wire | Vorträge auf dem 94. Kongress der European Atherosclerosis Society (EAS) unterstreichen die Breite der Evidenz für Bempedoinsäure bei einer Vielzahl von Patientengruppen und Hintergrundtherapien.... ► Artikel lesen | |
| 26.05. | Daiichi Sankyo Europe Reaffirms Commitment to Patient-Centred Care with Extensive Data Showcase at EAS Congress 2026 | 382 | Business Wire | Presentations at the 94th European Atherosclerosis Society (EAS) Congress highlight the breadth of evidence for bempedoic acid across a wide range of patient subgroups and background therapies.... ► Artikel lesen | |
| DAIICHI SANKYO CO LTD ADR Aktie jetzt für 0€ handeln | |||||
| 26.05. | AstraZeneca, Daiichi Sankyo Get Positive CHMP Opinion For Enhertu In HER2-Positive Solid Tumours | 348 | AFX News | LONDON (dpa-AFX) - AstraZeneca PLC (AZN) on Tuesday said the Committee for Medicinal Products for Human Use of the European Medicines Agency recommended approval of Enhertu, co-developed with... ► Artikel lesen | |
| 25.05. | AstraZeneca, Daiichi Drug Approved as New First-Line Therapy for Tough Type of Breast Cancer | 7 | MedCity News | ||
| 25.05. | AstraZeneca, Daiichi Sankyo's Datroway receives FDA approval for TNBC | 8 | Pharmaceutical Technology | ||
| 22.05. | AstraZeneca, Daiichi beat Gilead to first-line TNBC with FDA nod for Datroway | 19 | FiercePharma | ||
| 22.05. | AstraZeneca and Daiichi cancer drugs clear regulatory hurdles | 5 | Alliance News | ||
| 22.05. | AstraZeneca, Daiichi Sankyo's Datroway Gets Approval In US For Treatment Of Breast Cancer | 597 | AFX News | LONDON (dpa-AFX) - Friday, AstraZeneca PLC (AZN) along with Daiichi Sankyo (DSKYF.PK) announced that Datroway has been approved in the U.S. for the treatment of adult patients with unresectable... ► Artikel lesen | |
| 22.05. | Daiichi Sankyo: Enhertu Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors | 456 | Business Wire | Enhertu(trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry... ► Artikel lesen | |
| 18.05. | AstraZeneca, Daiichi Sankyo's Enhertu Gets New US Approval for Two HER2-Positive Breast Cancer Indications | 2 | Contract Pharma | ||
| 18.05. | AZN, Daiichi's Enhertu Gets FDA Nod for Two New Breast Cancer Settings | 6 | Zacks | ||
| 18.05. | Daiichi, AstraZeneca's Enhertu breaks into early breast cancer with dual FDA approvals | 10 | FiercePharma | ||
| 15.05. | Daiichi Life FY26 Earnings Slip Despite Higher Revenue; Guides FY27 | 458 | AFX News | TOKYO (dpa-AFX) - Daiichi Life Group, Inc. (DLICY, DCNSF, 8750.T), a Japanese insurance holding company, on Friday, reported net income declined despite an increase in revenue in the full year... ► Artikel lesen | |
| 13.05. | DAIICHI Kensetsu Corp. Full Year Sales Increase | 11 | RTTNews | ||
| 12.05. | Daiichi Sankyo bets on new cancer drugs to fuel future growth | 17 | Japan Times | ||
| 12.05. | Daiichi Jitsugyo Co Ltd Full Year Income Climbs | 5 | RTTNews | ||
| 11.05. | Daiichi Sankyo targets global top 5 oncology rank by 2035, $1.3B efficiency drive in new 5-year plan | 10 | FiercePharma | ||
| 11.05. | Daiichi Sankyo GAAP EPS of ¥140.44, revenue of ¥2.12B | 15 | Seeking Alpha | ||
| 11.05. | Daiichi Sankyo: Onkologie-Sparte treibt Umsatzwachstum um 12,6 % an | 17 | Investing.com Deutsch |
1 2 3 4 5 Weiter >>
128 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PFIZER | 22,020 | -0,07 % | BARCLAYS stuft PFIZER INC auf 'Underweight' | LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat die Einstufung für Pfizer mit einem Kursziel von 25 US-Dollar auf "Underweight" belassen. Angesichts der bisherigen Erfahrungen... ► Artikel lesen | |
| GILEAD SCIENCES | 112,40 | -0,27 % | Während Merck, Amgen, Novo Nordisk und Fresenius Milliarden bewegen, wächst die Fantasie im Zelltherapie-Sektor | ||
| VIATRIS | 13,632 | +0,26 % | Dividendenbekanntmachungen (22.05.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) 3M COMPANY US88579Y1010 0,78 USD 0,6712 EUR ACCO BRANDS CORPORATION US00081T1088 0,075 USD 0,0645 EUR ADVANCED ENERGY INDUSTRIES... ► Artikel lesen | |
| BIONANO GENOMICS | 1,250 | 0,00 % | Bionano Genomics: Bionano Announces Full Retirement of Outstanding Senior Secured Convertible Debentures | ||
| ACHIEVE LIFE SCIENCES | 4,480 | +0,90 % | Achieve Life Sciences Strengthens Board and Commercial Leadership with Three Senior Appointments from Team Previously at Verona Pharma | SEATTLE and VANCOUVER, British Columbia, May 12, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve and the Company) (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused... ► Artikel lesen | |
| JAZZ PHARMACEUTICALS | 198,85 | -0,58 % | Jazz Pharmaceuticals plc: Phase 3 HERIZON-GEA-01 Results Published in The New England Journal of Medicine Show Durable and Consistent Survival Benefit with Ziihera (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic ... | Expanded safety, subgroup, progression-free survival sensitivity and subsequent therapy analyses further characterize the consistency and durability of outcomes... ► Artikel lesen | |
| DAIICHI SANKYO | 14,032 | -1,18 % | Daiichi Sankyo Europe GmbH: Daiichi Sankyo Europe bekräftigt sein Engagement für eine patientenorientierte Versorgung mit einer umfassenden Datenpräsentation auf dem EAS-Kongress 2026 | Vorträge auf dem 94. Kongress der European Atherosclerosis Society (EAS) unterstreichen die Breite der Evidenz für Bempedoinsäure bei einer Vielzahl von Patientengruppen und Hintergrundtherapien.... ► Artikel lesen | |
| MADRIGAL PHARMACEUTICALS | 417,60 | +0,85 % | Citizens reiterates Madrigal Pharmaceuticals stock rating on liver data | ||
| OPUS GENETICS | 3,860 | +8,43 % | Opus Genetics, Inc.: Opus Genetics to Host Virtual R&D Science Forum on Tuesday, June 16, 2026 Featuring Multiple Inherited Retinal Disease Experts | ||
| SAVARA | 4,283 | -3,62 % | Savara Inc.: Savara Announces the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) Has Accepted the MOLBREEVI* Marketing Authorisation Application (MAA) for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) | -- MHRA's Acceptance Follows Acceptance/Validation of MOLBREEVI Biologics License Application (BLA) and MAA in Autoimmune PAP by the U.S. Food and Drug Administration (FDA) and the European Medicines... ► Artikel lesen | |
| NRX PHARMACEUTICALS | 4,090 | +2,76 % | NRx Pharmaceuticals, Inc.: NRx Pharmaceuticals (Nasdaq: NRXP) Strategic Partner Emobot Presents Late-Breaking Clinical Validation of the EMOCARE Depression Thermometer at ASCP 2026 | ||
| BIOHAVEN | 9,600 | -2,40 % | Biohaven Ltd.: Biohaven Reports First-in-Human Dosing of Oral PKM2 Modulator, BHV-8100, Targeting Metabolic Restoration and Immunomodulation | BHV-8100 is an orally administered, brain-penetrant PKM2 modulator; a novel therapeutic class addressing the bioenergetic and immunometabolic basis of systemic and central nervous system... ► Artikel lesen | |
| SKYE BIOSCIENCE | 0,605 | -2,42 % | Skye Bioscience, Inc. - 8-K, Current Report | ||
| MAIA BIOTECHNOLOGY | 1,305 | 0,00 % | MAIA Biotechnology, Inc.: MAIA Biotechnology Activates First U.S. Site for Ongoing International Phase 2 Expansion Trial of Novel Telomere Targeting Treatment Targeting Advanced Non-Small Cell Lung Cancer | Exceptional measures of efficacy observed in THIO-101 Phase 2 trial to date include disease control, response rates, and survival data well above standard of care benchmarks 50,000 advanced NSCLC... ► Artikel lesen | |
| BAYER | 33,350 | -5,07 % | Märkte am Morgen: Delivery Hero, MTU, Lufthansa, TUI, Airbus, Bayer, Space X | Nach der außergewöhnlichen Feiertagskonstellation - Pfingstmontag mit Handel in Deutschland, Memorial Day ohne Handel in den USA - tritt der DAX heute leicht auf die Bremse (-0,3 % erwartet). Gestern... ► Artikel lesen |
DAIICHI SANKYO CO LTD ADR gehört der Branche Pharma an. Der aktuelle Kurs liegt bei 13,300 Euro und damit -2,92 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu DAIICHI SANKYO CO LTD ADR finden Sie auf Wallstreet Online.